2020

Duopharma Biotech Posts Another Strong Quarter Registering PBT of RM18.57 Million

KUALA LUMPUR, 12 NOVEMBER 2020 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has posted a solid set of financial results for the third quarter ended 30 September 2020 with profit before tax holding steady at RM18.57 million (2019: RM19.77 million) against revenue of RM133.77 million (2019: RM142.86 million) despite impact of Covid-19 pandemic.

Breast Cancer and Chronic Myloid Leukaemia Community Welcome Manufacturing og Relevant Drugs at Malaysia’s First HAPI Facility

Duopharma HAPI Sdn Bhd to embark on CML drug after successful production and commercialisation of breast cancer theraphy.

Duopharma Biotech’s CHAMPS Joins Forces With Nasom To Propel Autism Awareness To A New Level In Malaysia

KUALA LUMPUR, 2 NOVEMBER 2020 – This year’s CHAMPS-NASOM Autism Awareness campaign in Malaysia has advanced to a new level as a result of wider industry collaboration, according to the National Autism Society of Malaysia (“NASOM”) and CHAMPS – Mothers’ Choice for Champions, the established child health supplement brand from the Consumer Healthcare (“CHC”) arm of leading pharmaceutical company Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”).

Duopharma Biotech’s CHAMPS™ Joins Forces With NASOM To Propel Autism Awareness To A New Level In Malaysia

Growing industry collaboration will reinforce CHAMPS-NASOM Autism Awareness Campaign into the future, says Duopharma Biotech Group MD
2020 CHAMPS-NASOM Autism Awareness Campaign, which marks the fourth year of Champs’ support of NASOM’s nation-wide drive to boost public awareness and acceptance of Autism, includes a contribution of RM50,000

Duopharma Biotech To Manufacture Its Second Oncology Medicine To Treat Chronic Myeloid Leukemia

Shah Alam, September 15, 2020 – Home-grown and rapidly evolving pharmaceutical industry player, Duopharma Biotech Berhad (“Duopharma Biotech” or the “Company”) through its wholly owned subsidiary, Duopharma HAPI Sdn Bhd will soon embark on manufacturing its second oncology drug at its first in Malaysia, Highly Potent Active Pharmaceutical Ingredient (HAPI) Plant in Shah Alam, to help address the paucity of affordable alternatives to treat cancer.

Duopharma Biotech Posts Creditable Q2 with PBT Climbing to RM19.39 Million

KUALA LUMPUR, 13 AUGUST 2020 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has posted a creditable set of financial results for the second quarter ended 30 June 2020 with profit before tax climbing to RM19.39 million (2019: RM18.32 million) against revenue of RM143.33 million (2019: RM145.47 million).

Halal Development Corporation, Duopharma Biotech and KPJ Join Forces to Boost The Global Halal Market in a Successful Webinar in conjunction with the World Halal Conference 2020

Kuala Lumpur, 28th July 2020 – Around 500 top industry players gathered online to participate in a webinar held in conjunction with the World Halal Conference (WHC) 2020 webinar series spotlighting the halal pharmaceutical industry.The webinar, entitled ‘Embracing a Halal Pharmaceutical Eco-System’, was organised by the Halal Development Corporation (HDC) in collaboration with Duopharma Biotech Berhad (Duopharma Biotech), and KPJ Healthcare Berhad (KPJ) hosted by the Ministry of International Trade and Industry (MITI).

Venturetech Announces New RM15 Million Investment Through Triparte MOU with Duopharma Biotect BHD and Commercial Biosimilar Production Facility

PUTRAJAYA, 17 July – VentureTECH today signed and exchanged a tripartite Memorandum of
Understanding (MoU) with Duopharma Biotech Bhd (Duopharma Biotech) and PanGen Biotech
Inc. (PanGen) toward the establishment of Malaysia’s first commercial biosimilar production
facility in a move to position the country as a regional player in the growing biosimilar market,
whilst improving affordability and accessibility to healthcare in the country.
The MoU signing ceremony was graced and witnessed by the Minister of Science, Technology,
and Innovation (MOSTI), YB Khairy Jamaluddin.

VentureTECH Announce New RM15 Million Investment Through Triparte MOU with Duopharma Biotech Bhd and Pangen Biotech Inc. to Build Malaysia’s First Commercial Biosimilar Production Facility

PUTRAJAYA, 17 July 2020 – VentureTECH today signed and exchanged a tripartite Memorandum of Understanding (MoU) with Duopharma Biotech Bhd (Duopharma Biotech) and PanGen Biotech Inc. (PanGen) toward the establishment of Malaysia’s first commercial biosimilar production facility in a move to position the country as a regional player in the growing biosimilar market, whilst improving affordability and accessibility to healthcare in the country.

Duopharma Biotech Maintains Positive Trajectory Despite Highly Challenging Environment

Duopharma Biotech Berhad’s 19th – and first ever fully virtual – AGM reinforces the Group’s dynamic aim of evolving as a pharmaceutical and healthcare leader with significant milestones during its second year as an independent entity
Strong business fundamentals and core values of the Group are fuelling onward progress through the coronavirus crisis, said Duopharma Biotech leadership